Company Overview of Tetragenex Pharmaceuticals, Inc.
Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The company’s principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. It also develops other central nervous systems active peptides, as second-generation medications for the treatment of depression, anxiety, and other psychiatric disorders. The company is headquartered in Syosset, New York.
6901 Jericho Turnpike
Syosset, NY 11791
Key Executives for Tetragenex Pharmaceuticals, Inc.
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3D Bio Holdings LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
To contact Tetragenex Pharmaceuticals, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.